medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-15-116-122medsovet-2680Research ArticleРациональная фармакотерапияRational pharmacotherapyФиксированная комбинация адреномиметика и холино блокатора 12-часового действия в новом устройстве доставки: аналитический обзор12-Hour fixed-dose combination of andrenergic agonist and cholinergic antagonist in a new administration device: analytical reviewВизельА. А.VizelA. A.

Визель Александр Андреевич – доктор медицинских наук, профессор, заведующий кафедрой фтизиопульмонологии

ВизельИ. Ю.VizelI. Yu.

Визель Ирина Юрьевна – доктор медицинских наук, доцент кафедры фтизиопульмонологии

ФГБОУ ВО Казанский государственный медицинский университет Минздрава РоссииРоссияKazan State Medical University of the Ministry of Health of RussiaRussian Federation201811102018015116122Copyright © Визель А.А., Визель И.Ю., 20182018Визель А.А., Визель И.Ю.Vizel A.A., Vizel I.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2680

Представлен аналитический обзор применения аклидиния, формотерола и сочетания «формотерол/аклидиний» при ХОБЛ при доставке фиксированной комбинации посредством дозирующего порошкового ингалятора Дженуэйр®. Отмечено, что двойная бронходилатация с 12-часовым эффектом имеет свои преимущества, состоящие в быстрой элиминации препаратов с минимальными системными эффектами, значительным влиянием на одышку и скоростные показатели выдоха, в рентабельности применения данного препарата. Доказано, что Дженуэйр® является новым удобным, простым в использовании в любом возрасте порошковым ингалятором с информативным механизмом обратной связи. Все это делает новую фиксированную комбинацию бронхолитиков в инновационном устройстве перспективным средством базисной терапии ХОБЛ.

The article presents an analytical review of the use of aclidinium, formoterol, and combination of aclidinium and formoterol to treat chronic obstructive pulmonary disease (COPD) using a metered-dose dry powder inhaler Genuair® to administer a fixeddose combination. It is noted that twelve hours’ double bronchodilating effect has some advantages including the rapid elimination of drugs having minimal systemic effects, significant effect on dyspnoea and exhalation rates, profitability of using this drug. It is proven that Genuair® is a new, patient-friendly, easy to administer at any age powder inhaler with an informative feedback mechanism. All this makes it possible to consider a new fixed-dose combination of bronchodilators in the innovative device to be a promising basic therapy for COPD.

ХОБЛдвойная бронходилатацияаклидиния бромидформотеролДженуэйрCOPDdouble bronchodilationaclidiniumformoterolGenuairReferencesGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): 2018 report, 2018: 123 p.www.coldcopd.prg.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): 2018 report, 2018: 123 p.www.coldcopd.prg.Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология, 2014, 24(3): 15–36.Chuchalin AG, Avdeev SN, Aisanov ZR, et al. Federal clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonologiya, 2014, 24 (3): 15-36Incorvaia C, Montagni M, Makri E, Ridolo E. New combinations in the treatment of COPD: rationale for aclidinium-formoterol. Ther Clin Risk Manag, 2016, 12: 209-215.Incorvaia C, Montagni M, Makri E, Ridolo E. New combinations in the treatment of COPD: rationale for aclidinium-formoterol. Ther Clin Risk Manag, 2016, 12: 209-215.Malo JL, Cartier A, Trudeau C, Ghezzo H, Gontovnick L. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilationin duced bronchoconstriction. Am Rev Respir Dis, 1990, 142(5): 1147-1152.Malo JL, Cartier A, Trudeau C, Ghezzo H, Gontovnick L. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilationin duced bronchoconstriction. Am Rev Respir Dis, 1990, 142(5): 1147-1152.Prat M, Fernández D, Buil MA et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and longacting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3{[hydroxy(di-2-thienyl)ace. J Med Chem, 2009, 52(16): 5076–5092.Prat M, Fernández D, Buil MA et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and longacting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3{[hydroxy(di-2-thienyl)ace. J Med Chem, 2009, 52(16): 5076–5092.Gavalda A, Miralpeix M, Ramos I et al. Charac terization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp The, 2009, 331(2): 740–751.Gavalda A, Miralpeix M, Ramos I et al. Charac terization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp The, 2009, 331(2): 740–751.Beier J, Kirsten AM, Mrûz R, Segarra R, Chuecos F, Caracta C, Gil EG. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase IIIb Study. COPD, 2013, 10(4): 511-522.Beier J, Kirsten AM, Mrûz R, Segarra R, Chuecos F, Caracta C, Gil EG. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase IIIb Study. COPD, 2013, 10(4): 511-522.Wedzicha JA, Agusti A, Donaldson G, Chuecos F, Lamarca R, Garcia Gil E. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: A pooled analysis of five phase iii, randomized, placebo-controlled studies. COPD, 2016, 13(6): 669-676.Wedzicha JA, Agusti A, Donaldson G, Chuecos F, Lamarca R, Garcia Gil E. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: A pooled analysis of five phase iii, randomized, placebo-controlled studies. COPD, 2016, 13(6): 669-676.Naline E, Grassin Delyle S, Salvator H, Brollo M, Faisy C, Victoni T, Abrial C, Devillier P. Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulm Pharmacol Ther, 2018, 49: 46-53.Naline E, Grassin Delyle S, Salvator H, Brollo M, Faisy C, Victoni T, Abrial C, Devillier P. Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulm Pharmacol Ther, 2018, 49: 46-53.Malerba M, Radaeli A, Santini G, Morjaria J, Mores N, Mondino C, Macis G, Montuschi P. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov, 2018 Apr 4: 1-15. doi: 10.1080/17460441.2018.1455661.Malerba M, Radaeli A, Santini G, Morjaria J, Mores N, Mondino C, Macis G, Montuschi P. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov, 2018 Apr 4: 1-15. doi: 10.1080/17460441.2018.1455661.Bateman ED, Chapman KR, Singh D, D’Urzo AD, Molins E, Leselbaum A, Gil EG. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two sixmonth, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res, 2015, 16: 92. doi: 10.1186/s12931-015-0250-2.Bateman ED, Chapman KR, Singh D, D’Urzo AD, Molins E, Leselbaum A, Gil EG. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two sixmonth, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res, 2015, 16: 92. doi: 10.1186/s12931-015-0250-2.Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2041-2053.Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2041-2053.Ramos M, Haughney J, Henry N, Lindner L, Lamotte M. Cost versus utility of aclidinium bromide 400 μg plus formoterol fumarate dihydrate 12 μg compared to aclidinium bromide 400 μg alone in the management of moderate-to-severe COPD. Clinicoecon Outcomes Res, 2016, 8: 445-456.Ramos M, Haughney J, Henry N, Lindner L, Lamotte M. Cost versus utility of aclidinium bromide 400 μg plus formoterol fumarate dihydrate 12 μg compared to aclidinium bromide 400 μg alone in the management of moderate-to-severe COPD. Clinicoecon Outcomes Res, 2016, 8: 445-456.Singh D, D’Urzo AD, Chuecos F, Muñoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res, 2017, 18(1): 106.Singh D, D’Urzo AD, Chuecos F, Muñoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res, 2017, 18(1): 106.Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis, 2017, 12: 34693485.Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis, 2017, 12: 34693485.Capel M, Mareque M, Álvarez CJ, Lindner L, Oyagüez I. Cost-Effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig, 2018 Apr 13. doi:10.1007/s40261018-0646-0. [Epub ahead of print]Capel M, Mareque M, Álvarez CJ, Lindner L, Oyagüez I. Cost-Effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig, 2018 Apr 13. doi:10.1007/s40261018-0646-0. [Epub ahead of print]Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Beier J, Seoane B, Segarra RM, Leselbaum A. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J, 2016, 48(4): 1030-1039.Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Beier J, Seoane B, Segarra RM, Leselbaum A. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J, 2016, 48(4): 1030-1039.Medic G, Lindner L, van der Weijden M, Karabis A. Efficacy and safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an indirect treatment comparison. Adv Ther, 2016, 33(3): 379-399.Medic G, Lindner L, van der Weijden M, Karabis A. Efficacy and safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an indirect treatment comparison. Adv Ther, 2016, 33(3): 379-399.Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2545-2558.Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2545-2558.der Palen Jv. Genuair(®) in chronic obstructive pulmonary disease: a novel, user-friendly, multidose, dry-powder inhaler. Ther Deliv, 2014, 5(7): 795-806.der Palen Jv. Genuair(®) in chronic obstructive pulmonary disease: a novel, user-friendly, multidose, dry-powder inhaler. Ther Deliv, 2014, 5(7): 795-806.Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, Jarreta D, Garcia Gil E. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med, 2009, 103(12): 1832-1837.Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, Jarreta D, Garcia Gil E. Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med, 2009, 103(12): 1832-1837.Krüger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). European Respiratory Journal., 2014, 44: 4635.Krüger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). European Respiratory Journal., 2014, 44: 4635.Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration, 2009, 78(3): 322-328.Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration, 2009, 78(3): 322-328.Blasi F, Canonica GW, Centanni S, Mereu C, Bernabei R, Paolisso G, Incalzi RA, Corsico A, Di Marco F, Milanese M, Pagano F, Santus P, Scichilone N, Sumberesi M, Braido F, Baiardini I. Genuair® usability test: Results of a national public survey of the elderly. COPD, 2016, 13(3): 367-371.Blasi F, Canonica GW, Centanni S, Mereu C, Bernabei R, Paolisso G, Incalzi RA, Corsico A, Di Marco F, Milanese M, Pagano F, Santus P, Scichilone N, Sumberesi M, Braido F, Baiardini I. Genuair® usability test: Results of a national public survey of the elderly. COPD, 2016, 13(3): 367-371.García-Río F, Soler-Cataluña JJ, Alcazar B, Viejo JL, Miravitlles M. Requirements, strengths and weaknesses of inhaler devices for COPD patients from the expert prescribers’ point of view: results of the EPOCA Delphi consensus. COPD, 2017, 14(6): 573-580.García-Río F, Soler-Cataluña JJ, Alcazar B, Viejo JL, Miravitlles M. Requirements, strengths and weaknesses of inhaler devices for COPD patients from the expert prescribers’ point of view: results of the EPOCA Delphi consensus. COPD, 2017, 14(6): 573-580.Bournival R, Coutu R, Goettel N, Yang CD, Cantin-Lafleur A, Lemieux C, Lévesque AM, Patenaude-Monette JF, Roy FO, Blais L, Arbour F, Fillion A, Beauchesne MF. Preferences and inhalation techniques for inhaler devices used by patients with chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Deliv, 2017 Dec 5. doi:10.1089/jamp.2017.1409.Bournival R, Coutu R, Goettel N, Yang CD, Cantin-Lafleur A, Lemieux C, Lévesque AM, Patenaude-Monette JF, Roy FO, Blais L, Arbour F, Fillion A, Beauchesne MF. Preferences and inhalation techniques for inhaler devices used by patients with chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Deliv, 2017 Dec 5. doi:10.1089/jamp.2017.1409.Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS. Factors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey Int J Chron Obstruct Pulmon Dis, 2018, 13: 695-702.Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS. Factors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey Int J Chron Obstruct Pulmon Dis, 2018, 13: 695-702.Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis, 2017, 12: 1565-1577.Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis, 2017, 12: 1565-1577.

The authors declare that there are no conflicts of interest present.